Every day, our immune system clears away billions of damaged or dying cells. This vital housekeeping, carried out by phagocytes, ensures tissue health and balance. When the process falters, harmful cells may persist, fueling diseases like cancer or autoimmunity.
Researchers at Kyoto University have now engineered a novel protein tool – Crunch (Connector for Removal of Unwanted Cell Habitat) – to redirect this natural mechanism toward living, disease-causing cells. The study, described in Nature Biomedical Engineering, demonstrates that Crunch represents a new therapeutic approach that could expand the applications of precision medicine.
Traditionally, phagocytosis targets cells displaying “eat-me” signals, such as phosphatidylserine, exposed during apoptosis. Crunch reprograms this system: instead of binding dying cells, it can be tailored to recognize surface proteins specific to harmful cells – such as tumor cells or autoreactive immune cells. Once attached, it bridges the target with phagocytes, leading to engulfment and elimination.
In preclinical models, the tool demonstrated dual potential: removing cancer cells engineered to express specific antigens, and reducing pathogenic immune cells in lupus. In both cases, clearance correlated with an alleviation of disease signs.
This approach differs from established therapies. CAR T-cell treatments require complex ex vivo engineering, while antibody drugs rely on immune-mediated cytotoxicity. Crunch, by contrast, is a protein-based modality that could be administered by injection and flexibly adapted by swapping recognition domains. In principle, it merges the modularity of antibodies with the natural efficiency of cellular waste disposal.
The implications are significant. If optimized for safety and scalability, Crunch could usher in therapies that act as a biological cleanup crew—precisely eliminating the cells that drive pathology while sparing healthy tissue. Beyond oncology and autoimmunity, applications could extend to chronic inflammation or transplant medicine.
At its core, this innovation is about reimagining an ancient immune function for modern therapeutics: leveraging phagocytosis not just for passive clearance, but as an active, programmable weapon against disease.
Leave a Reply